Zhilong Yan Selected Research

Neoplasms (Cancer)

12/2023	Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial.
7/2023	The estrogen/miR-338-3p/ADAM17 axis enhances the viability of breast cancer cells via suppressing NK cell's function.
1/2023	Linc-ROR Regulates POU5F1 and SOX2 by Competitively Binding miR-145-5p to Affect the Proliferation and Migration of Gastric Cancer Cells.
2/2022	Ailanthone suppresses the activity of human colorectal cancer cells through the STAT3 signaling pathway.
1/2021	tRNA-derived fragments: Mechanisms underlying their regulation of gene expression and potential applications as therapeutic targets in cancers and virus infections.
1/2021	Global profile of tRNA-derived small RNAs in gastric cancer patient plasma and identification of tRF-33-P4R8YP9LON4VDP as a new tumor suppressor.
8/2020	Ailanthone: A novel potential drug for treating human cancer.
3/2020	Reduced expression of circRNA hsa_circ_0067582 in human gastric cancer and its potential diagnostic values.
1/2020	Downregulated Expression of linc-ROR in Gastric Cancer and Its Potential Diagnostic and Prognosis Value.
1/2020	Krüppel-like factor 9 promotes neuroblastoma differentiation via targeting the sonic hedgehog signaling pathway.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Zhilong Yan Research Topics

Disease

12	Neoplasms (Cancer) 12/2023 - 08/2015
9	Stomach Neoplasms (Stomach Cancer) 01/2023 - 01/2019
2	Adenocarcinoma 12/2023 - 01/2021
2	Breast Neoplasms (Breast Cancer) 07/2023 - 01/2021
2	Melanoma (Melanoma, Malignant) 05/2022 - 01/2017
1	Anemia 12/2023
1	Colorectal Neoplasms (Colorectal Cancer) 02/2022
1	Prostatic Neoplasms (Prostate Cancer) 01/2021
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2021
1	Virus Diseases (Viral Diseases) 01/2021
1	Liver Neoplasms (Liver Cancer) 01/2021
1	Neuroblastoma 01/2020
1	Hypoxia (Hypoxemia) 11/2018
1	Disease Progression 01/2017
1	Pancreatic Neoplasms (Pancreatic Cancer) 08/2015
1	Neoplasm Metastasis (Metastasis) 08/2015
1	Hepatic Encephalopathy 12/2012
1	Hemorrhage 12/2012
1	Portal Hypertension 12/2012
1	Hypersplenism (Anemia, Splenic) 12/2012
1	Esophageal and Gastric Varices (Esophageal Varices) 12/2012
1	Pathologic Constriction (Stenosis) 12/2012
1	Fistula 06/2009
1	Esophageal Atresia 06/2009

Drug/Important Bio-Agent (IBA)

6	Biomarkers (Surrogate Marker)IBA 01/2021 - 08/2015
3	Transfer RNA (tRNA)IBA 01/2021 - 11/2018
3	Tumor Biomarkers (Tumor Markers)IBA 03/2020 - 01/2019
2	ailanthoneIBA 02/2022 - 08/2020
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 02/2022 - 01/2021
1	sintilimabIBA 12/2023
1	Estrogens (Estrogen)FDA Link 07/2023
1	MicroRNAs (MicroRNA)IBA 07/2023
1	Competitive Endogenous RNAIBA 01/2023
1	Long Noncoding RNAIBA 01/2023
1	Small Interfering RNA (siRNA)IBA 01/2023
1	Leucovorin (Folinic Acid)FDA Link 02/2022
1	Fluorouracil (Carac)FDA LinkGeneric 02/2022
1	QuassinsIBA 02/2022
1	130-nm albumin-bound paclitaxelIBA 01/2021
1	Capecitabine (Xeloda)FDA Link 01/2021
1	Albumin-Bound Paclitaxel FDA Link 01/2021
1	XELOXIBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Circular RNAIBA 03/2020
1	AntigensIBA 03/2020
1	CarbohydratesIBA 03/2020
1	Factor IX (Coagulation Factor IX)FDA LinkGeneric 01/2020
1	angiogeninIBA 11/2018
1	Messenger RNA (mRNA)IBA 01/2017
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2017
1	Proteins (Proteins, Gene)FDA Link 08/2015
1	BariumIBA 12/2012
1	AmmoniaIBA 12/2012

Therapy/Procedure

4	Drug Therapy (Chemotherapy) 12/2023 - 08/2020
2	Gastrectomy 01/2022 - 01/2021
2	Therapeutics 01/2021 - 08/2015
1	Treatment Delay 05/2022
1	Adjuvant Chemotherapy 01/2021
1	Immunotherapy 01/2017
1	Splenectomy 12/2012
1	Sclerotherapy 12/2012
1	Ligation 06/2009